Medicenna Therapeutics Corp(MDNA-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.4300
Day High0.4450
Open:0.4450
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
GlobeNewswire
Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
GlobeNewswire
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
GlobeNewswire
Medicenna Announces the Launch of a Marketed Public Offering of Securities
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
GlobeNewswire
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
GlobeNewswire
Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
GlobeNewswire
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
GlobeNewswire
Medicenna Therapeutics Announces Participation in Upcoming Conferences
GlobeNewswire
Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
GlobeNewswire
Medicenna Announces Changes to Board Composition

Profile

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.